Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Consensus Recommendation of "Hold" by Brokerages

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) have received an average rating of "Hold" from the nine research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $26.67.

PCRX has been the topic of several recent analyst reports. HC Wainwright lifted their price objective on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research note on Tuesday, April 8th. Truist Financial raised shares of Pacira BioSciences from a "sell" rating to a "hold" rating and boosted their price target for the company from $8.00 to $25.00 in a report on Thursday, January 30th. Barclays raised their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $18.00 price target on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $32.00 price objective on shares of Pacira BioSciences in a research report on Tuesday, April 8th.

Pacira BioSciences Trading Down 0.6 %

Shares of PCRX stock traded down $0.15 on Tuesday, reaching $26.75. 585,142 shares of the stock were exchanged, compared to its average volume of 986,078. The stock has a 50 day moving average price of $24.58 and a 200 day moving average price of $21.68. Pacira BioSciences has a one year low of $11.16 and a one year high of $31.67. The stock has a market cap of $1.24 billion, a PE ratio of -13.18 and a beta of 0.71. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89.

Institutional Trading of Pacira BioSciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Hennion & Walsh Asset Management Inc. grew its holdings in shares of Pacira BioSciences by 18.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 56,385 shares of the company's stock valued at $1,062,000 after acquiring an additional 8,636 shares in the last quarter. Nisa Investment Advisors LLC raised its position in shares of Pacira BioSciences by 495.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock valued at $62,000 after purchasing an additional 2,749 shares during the period. Gagnon Securities LLC lifted its position in Pacira BioSciences by 4.8% during the fourth quarter. Gagnon Securities LLC now owns 321,743 shares of the company's stock worth $6,062,000 after acquiring an additional 14,800 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Pacira BioSciences by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock worth $184,000 after acquiring an additional 918 shares during the period. Finally, Caitlin John LLC grew its position in shares of Pacira BioSciences by 1,850.0% in the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company's stock valued at $35,000 after purchasing an additional 1,776 shares during the last quarter. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.